• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fuhrman grading is inappropriate for papillary renal cell carcinoma.

作者信息

Delahunt Brett, Egevad Lars, Srigley John R, Samaratunga Hemamali

机构信息

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, PO Box 7343, Wellington, New Zealand.

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

出版信息

World J Urol. 2018 Aug;36(8):1335-1336. doi: 10.1007/s00345-017-2153-y. Epub 2017 Dec 18.

DOI:10.1007/s00345-017-2153-y
PMID:29256019
Abstract
摘要

相似文献

1
Fuhrman grading is inappropriate for papillary renal cell carcinoma.福尔曼分级不适用于乳头状肾细胞癌。
World J Urol. 2018 Aug;36(8):1335-1336. doi: 10.1007/s00345-017-2153-y. Epub 2017 Dec 18.
2
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.透明细胞肾细胞癌：世界卫生组织/国际泌尿病理学会分级的验证。
Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.
3
The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.嫌色细胞肿瘤分级系统是嫌色性肾细胞癌的首选分级方案。
J Urol. 2011 Dec;186(6):2168-74. doi: 10.1016/j.juro.2011.07.068. Epub 2011 Oct 19.
4
The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.福尔曼分级系统对非肉瘤样嗜色细胞肾细胞癌患者没有预后价值。
Hum Pathol. 2014 Dec;45(12):2411-6. doi: 10.1016/j.humpath.2014.08.002. Epub 2014 Aug 23.
5
[Renal cell carcinoma: pathological prognostic factors, staging and histopathological classification of 355 cases].[肾细胞癌：355例患者的病理预后因素、分期及组织病理学分类]
Rev Med Inst Mex Seguro Soc. 2015 Jul-Aug;53(4):454-65.
6
Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome.乳头状肾细胞癌：肿瘤分级和组织学特征与临床结局的相关性
Hum Pathol. 2015 Oct;46(10):1411-7. doi: 10.1016/j.humpath.2015.07.001. Epub 2015 Jul 15.
7
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma.双指数和单指数扩散加权成像在评估透明细胞肾细胞癌Fuhrman分级中的比较
Diagn Interv Radiol. 2017 Mar-Apr;23(2):100-105. doi: 10.5152/dir.2016.15519.
8
[The WHO/ISUP grading system for renal carcinoma].[世界卫生组织/国际泌尿病理学会肾癌分级系统]
Pathologe. 2016 Jul;37(4):355-60. doi: 10.1007/s00292-016-0171-y.
9
Intraobserver and interobserver variability of Fuhrman and modified Fuhrman grading systems for conventional renal cell carcinoma.Fuhrman 分级系统和改良 Fuhrman 分级系统在常规肾细胞癌中的观察者内和观察者间变异性。
Kaohsiung J Med Sci. 2009 Nov;25(11):596-600. doi: 10.1016/S1607-551X(09)70562-5.
10
Gleason and Fuhrman no longer make the grade.格里森（Gleason）和富尔曼（Fuhrman）评分系统不再适用。
Histopathology. 2016 Mar;68(4):475-81. doi: 10.1111/his.12803. Epub 2015 Nov 16.

引用本文的文献

1
Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma.比较 1 型和 2 型乳头状肾细胞癌的临床病理参数和肿瘤学结局。
BMC Urol. 2020 Sep 15;20(1):148. doi: 10.1186/s12894-020-00716-0.
2
Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery.术前中性粒细胞与淋巴细胞比值对非转移性乳头状肾细胞癌患者根治性手术后的预测价值。
Cancer Manag Res. 2019 Aug 7;11:7515-7524. doi: 10.2147/CMAR.S211727. eCollection 2019.
3
External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database.

本文引用的文献

1
Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.Fuhrman 分级和年龄对乳头状肾细胞癌患者癌症特异性和总体生存的预后意义：2189 例患者国际多机构研究的结果。
World J Urol. 2017 Dec;35(12):1891-1897. doi: 10.1007/s00345-017-2078-5. Epub 2017 Aug 23.
2
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.透明细胞肾细胞癌：世界卫生组织/国际泌尿病理学会分级的验证。
Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.
3
利用大型多中心数据库对用于预测乳头状肾细胞癌患者疾病特异性生存的术后列线图进行外部验证。
Int J Clin Oncol. 2020 Jan;25(1):145-150. doi: 10.1007/s10147-019-01530-x. Epub 2019 Aug 30.
Gleason and Fuhrman no longer make the grade.
格里森（Gleason）和富尔曼（Fuhrman）评分系统不再适用。
Histopathology. 2016 Mar;68(4):475-81. doi: 10.1111/his.12803. Epub 2015 Nov 16.
4
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.国际泌尿病理学会（ISUP）肾细胞癌分级系统及其他预后参数。
Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb.
5
A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.一种纳入肿瘤坏死的透明细胞肾细胞癌新型分级系统。
Am J Surg Pathol. 2013 Mar;37(3):311-22. doi: 10.1097/PAS.0b013e318270f71c.
6
Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma.与乳头状肾细胞癌患者预后相关的临床和病理特征。
J Urol. 2012 Jan;187(1):54-9. doi: 10.1016/j.juro.2011.09.053. Epub 2011 Nov 16.
7
Grading of clear cell renal cell carcinoma should be based on nucleolar prominence.透明细胞肾细胞癌的分级应基于核仁明显度。
Am J Surg Pathol. 2011 Aug;35(8):1134-9. doi: 10.1097/PAS.0b013e318220697f.
8
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.核仁分级比 Fuhrman 分级能为肾透明细胞乳头状癌提供更高的预后准确性。
J Urol. 2010 Jun;183(6):2143-7. doi: 10.1016/j.juro.2010.02.023.
9
Advances and controversies in grading and staging of renal cell carcinoma.肾细胞癌分级和分期的进展与争议
Mod Pathol. 2009 Jun;22 Suppl 2:S24-36. doi: 10.1038/modpathol.2008.183.
10
Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma.核仁分级而非福尔曼分级适用于乳头状肾细胞癌。
Am J Surg Pathol. 2006 Sep;30(9):1091-6. doi: 10.1097/01.pas.0000209833.69972.2b.